– SK Bioland plans to expand the indication for the ankle joint with clinical trials
– CARTISTEM^® extends its coverage to patients with ankle joints

MEDIPOST announced on Dec 31 with SK Bioland that it has signed a domestic exclusive sales agreement for the ankle joint indication of CARTISTEM^®.

Through this agreement, MEDIPOST will be in charge of the development and manufacture of CARTISTEM^®, and SK Bioland plans to conduct the clinical trials of the ankle joint expansion indications for domestic commercialization.

In addition, when the clinical trial is completed and the product registration is approved, SK Bioland will receive CARTISTEM^® from MEDIPOST, which will be sold exclusively to patients with the indications of ankle joints in Korea.

CARTISTEM^® was approved by the KFDA in January 2012 for the treatment of knee cartilage regeneration in patients with osteoarthritis due to degenerative or repetitive trauma. The world’s first allogeneic cord blood-derived mesenchymal stem cells have been shown to regenerate damaged cartilage tissue.

A MEDIPOST representative stated that, “based on our experience and trust in knee cartilage treatment for the past seven years, it is now essential that we extend our indications to patients with ankle joints.”

In addition, he/she said, “if the clinical trials are successful and sales begin, we will offer new treatment options to many patients with ankle joints in the absence of effective treatment methods”.